valu usd unless otherwis note
revenu guid soft ep guidanc
rais tax reform benefit
view report solid start ep guidanc
rais account benefit tax reform partial
off-set busi reinvest pt increas
report ep beat aid lower tax rate
announc preliminari revenu januari yesterday
provid full result revenu
guidanc y/i exclud cynosur blood
screen rbce non-gaap ep nickel
consensu guidanc due higher revenu
ep non-gaap consensu
oper expens ratio fce
revenu beat driven better ou breast health ww
cytolog perinat perform four fewer sell day
serv headwind breast health revenu
y/i rbce flat y/i highlight intern
breast growth y/i ww breast biopsi y/
diagnost revenu y/i exclud blood
screen rbce y/i molecular y/i rbce
cytology/perinat revenu y/i rbce y/i due
higher sale perinat product separ myosur revenu
increas y/i rbce novasur revenu
y/i rbce final cynosur revenu came
expect rbce due softer bodi revenu
ep guidanc rais account tax reform manag
re-affirmed revenu guidanc fce
separ non-gaap ep guidanc rais
vs fce account benefit
 tax reform partial off-set invest back
busi revenu guidanc came softer expect
fce final non-gaap ep guidanc
chang mid-single-digit y/i organ top-line growth estim
star show
grow y/i exclud cynosur blood screen
manag feel better breast health busi exit
gain share intern slow ge recent
momentum howev manag seen increas novasur
competit like minerva expect weak continu
next sever quarter regard cynosur manag see
strength intern skin believ still struggl
bit sculpsur good news reinvest
portion tax reform upsid cynosur gyn surgic market
speed initi sever project
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case price target calcul assign
weight intrins valu calcul ev/
ebitda analysi weight intrins
valu calcul price-to-earnings analysi
weight intrins valu calcul dcf
sh model organ top-lin growth medium
term ep growth y/i assum cynosur
busi return high-single-digit y/i revenu growth
period initi sale disrupt month also
assum molecular diagnost
achiev high-single-digit y/i growth medium term
upsid scenario valu model
organ top-lin growth next sever year
ep growth rang peer
assum cynosur busi return y/i
revenu growth period initi sale disrupt
month assum manag drive
sustain superior top-lin growth new contract
win product launch improv intern execut
increas sale forc add tuck-in
downsid scenario valu model organ top-
line growth low- mid-single-digit rang ep
growth rang assum tomo placement
slow ramp take longer
expect also myosur growth slow near peak
sale novasur continu declin due increas
competit separ assum cynosur sale disrupt
take longer work cynosur revenu growth
slow mid-singl digit y/i medium term final gen-
probe revenu growth fall short expect molecular
price pressures/reimburs pressur increas
believ share perform line
peer group follow key reason
multipl top-lin growth driver lead us
believ return top-lin growth y/i
medium term
molecular diagnost expect continu
take share hpv expand
trichomona market addit full menu viral
load test doubl holx world-wide molecular market
opportun addit recent brought
panther fusion respiratori assay
regard gyn surgic believ mid-single-digit y/i
growth sustain medium term main
growth driver myosur intern expans
addit believ tuck-in acquisit could expand
two product portfolio segment
intern breast health plenti
opportun convert analog user intern market
system could upgrad separ
intern molecular busi grown
y/i five last six quarter expect
magnitud growth continu also see
opportun increas current liquid
base cytolog market share intern market
share
believ cynosur return high-single-digit top-
line growth check suggest height sale
rep turnov although rep departur continu
fill capit rep vacanc end
believ cynosur return high-single-digit y/i
revenu growth initi period sale forc disrupt
transform sustain growth compani
cynosur growth profil still question believ
cynosur acceler weight averag market
growth rate y/i allow
achiev double-digit ep growth near-term period
initi sale disrupt howev await
evid acceler cynosur busi
becom posit share
risk invest thesi
cynosur growth recov bodi contour
market opportun smaller expect
manag spend drive cynosur growth
deriv price target assign weight intrins
valu calcul ev/ebitda analysi weight intrins
valu calcul price-to-earnings analysi weight intrins valu
calcul dcf analysi point averag forward ev/ebitda
multipl large-cap md compani lifesci tool diagnost averag
ev/ebitda averag forward price-to-earnings multipl large-cap md compani
lifesci tool diagnost averag price-to-earnings assign target non-gaap
ebitda multipl slightli large-cap md peer group
multipl equat intrins valu separ assign target forward
price-to-earnings multipl slightli large-cap md peer group
multipl equat intrins valu believ ev/ebitda price-to-earnings multipl
slightli peer warrant given less visibl abil sustain mid-single-
digit y/i top-line growth rel peer near term final base dcf analysi
estim intrins valu dcf analysi use wacc
termin valu ev/ebitda multipl price target support sector
risk rate price target
risk price target rate includ risk meaning delay new product
launch market share loss unforeseen chang regulatori environ
lead develop manufactur supplier diagnost product medic
imag surgic product market corpor headquart locat bedford
skelet health medic aesthet
million except per share data
sell market
gener administr
